CervoMed Inc（CRVO）股票分析

AI 分析 of CervoMed Inc (CRVO)

賣出

CervoMed Inc. is not a good buy right now due to its extremely low RSI of 11.45, indicating oversold conditions, and a significant year-to-date decline of 81.90%. While the gross margin is high at 100% for the last reported quarters, the company is facing severe financial challenges with a net income loss of -$7,964,158 in Q1 2026. The stock's recent performance shows a 5-day change of -11.88%, and it is currently trading at $1.41, far below its 52-week high of $10.00, indicating a lack of investor confidence and potential volatility ahead. The main risk is the ongoing financial losses and the uncertainty surrounding future financing and partnerships for clinical trials, which could further impact stock performance negatively.

估值指標

CervoMed Inc（CRVO）目前預期本益比為 0.00，5 年平均預期本益比為 -5.71。

預期本益比

高估

5 年均值 P/E

-5.71

目前P/E

0.00

高估

-2.21

低估

-9.21

預期 EV/EBITDA

合理

5 年均值 EV/EBITDA

-3.44

目前EV/EBITDA

0.01

高估

0.62

低估

-7.51

預期股價營收比

合理

5 年均值 P/S

27.83

目前P/S

26.31

高估

49.40

低估

6.26

CRVO 常見問題 —— 由 Alphio AI 解答

CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

CervoMed Inc. is not a good buy right now due to its extremely low RSI of 11.45, indicating oversold conditions, and a significant year-to-date decline of 81.90%. While the gross margin is high at 100% for the last reported quarters, the company is facing severe financial challenges with a net income loss of -$7,964,158 in Q1 2026. The stock's recent performance shows a 5-day change of -11.88%, and it is currently trading at $1.41, far below its 52-week high of $10.00, indicating a lack of investor confidence and potential volatility ahead. The main risk is the ongoing financial losses and the uncertainty surrounding future financing and partnerships for clinical trials, which could further impact stock performance negatively.